Statements (14)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
engineered bacterial strain
|
| gptkbp:administeredBy |
oral capsule
|
| gptkbp:clinicalTrialPhase |
Phase 2
|
| gptkbp:developedBy |
gptkb:Synlogic
|
| gptkbp:engineeredFor |
degradation of oxalate
|
| https://www.w3.org/2000/01/rdf-schema#label |
SYNB1934
|
| gptkbp:mechanismOfAction |
expresses oxalate-degrading enzymes
|
| gptkbp:organism |
gptkb:Escherichia_coli_Nissle_1917
|
| gptkbp:status |
investigational
|
| gptkbp:target |
gptkb:secondary_hyperoxaluria
gptkb:primary_hyperoxaluria |
| gptkbp:usedFor |
treatment of enteric hyperoxaluria
|
| gptkbp:bfsParent |
gptkb:Synthetic_Biotic_medicines
|
| gptkbp:bfsLayer |
7
|